-
-
-
-
-
-
-
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
-
-
-
-
-
-
-
Otonomy (OTIC) Appoints Jill Broadfoot to Board of Directors
-
-
-
-
-
-
-
After-Hours Stock Movers 04/07: (AVCT) (SBBP) (CARG) Higher; (OTIC) (LNDC) (ASO) Lower (more...)
-
-
-
-
-
-
-
Otonomy (OTIC) Provides Update on OTIVIDEX and OTO-313 Programs
-
-
-
-
-
-
-
Otonomy (OTIC) Provides Update on Clinical Trials, Development Programs
-
-
-
-
-
-
-
Otonomy (OTIC) Highlights Preclinical Results for GJB2 Gene Therapy Collaboration and Cisplatin Otoprotection Program
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

